Diligence memo · auto-generated · as of July 2, 2026
Verona Pharma plc
Verona Pharma plc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Verona Pharma plc operates in Pharmaceuticals, based in London.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Verona Pharma plc has raised $245M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $200M on 2020-07-22.
Most recent recorded round closed around 2020-07-22.
Valuation (modeled)modeled
Provath models Verona Pharma plc at approximately $7.0B (range $953M–$15.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.87× the median modeled value of Series D+ Pharmaceuticals companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 49 months.
Last raise 5.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Nuvation Bio Inc., Recursion Pharmaceuticals, Inc., Vyripharm Enterprises, Inc., Cingulate Inc., Day One Biopharmaceuticals Holding Co LLC.
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.